Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623362 | 0.85 | NR3C2 (0.44) | RECQLNR3C2TYK2PRKCAPRKCD | |
| SCHEMBL2056325 | 0.82 | NOS2 (0.53) | NR3C2TYK2RIOK2 | |
| SCHEMBL31325755 | 0.82 | NOS2 (0.53) | NR3C2TYK2RIOK2 | |
| SCHEMBL23021737 | 0.81 | RECQL (0.48) | RECQLABL1NR3C2TYK2HDAC1 | |
| SCHEMBL14076711 | 0.80 | PRMT6 (0.43) | NR3C2TYK2 | |
| SCHEMBL2643260 | 0.80 | NR3C2 (0.36) | NR3C2TYK2 | |
| SCHEMBL4311098 | 0.80 | TYK2 (0.39) | RECQLNR3C2TYK2 | |
| SCHEMBL5070476 | 0.80 | RECQL (0.52) | RECQLABL1NR3C2TYK2HDAC1 | |
| SCHEMBL2643263 | 0.80 | LOXL2 (0.52) | NR3C2 | |
| SCHEMBL2481330 | 0.79 | RECQL (0.47) | RECQLABL1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
| EP-3828173-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2019156929-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-3495358-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Bristol-Myers Squibb Company (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2015091584-A1 | THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015088564-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | BAYER HEALTHCARE AG (DE) | 2009-01-22 | — | — | US | disclosed |
| CN-1133625-C | Quinazoline derivatives | — | 2004-01-07 | — | — | CN | disclosed |
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| CN-1205694-A | Quinazoline derivatives | ZENECA LTD (GB) | 1999-01-20 | — | — | CN | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | RECQL 1574/4885ABL1 359/4885NR3C2 37/4885 |
| US-20090023753-A1 | 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents | MCL1, HDAC5, HDAC6 | RECQL 1898/4885ABL1 290/4885NR3C2 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.